SOHO 2023 | High-risk multiple myeloma: addressing challenges and unmet needs

High-risk myeloma makes up about a quarter of all newly diagnosed myeloma, and despite the fact that we have good treatments that have been developed over the past 10 to 15 years, high-risk myeloma remains an area of unmet need. What we mean by high-risk is, despite our initial therapies, patients have a high risk of the disease coming back within the first two years of diagnosis. Patients cycle through treatments quickly and will have lower overall survival compared to the other patients. So the data that I highlighted in my talk at the meeting was extrapolated from all the contemporary clinical trials that include both triplet and quadruplet induction therapies, highlighting the fact that many of the trials that have been done have included smaller subsets of high-risk patients. So, we’re really trying to make the best use of the data we have, in trying to come up with a schema to treat the high-risk patients. I also want to share the increase in the number of enrichment-design clinical trials that we’re doing for high-risk patients right now, compared to how things were being done five or six years ago. So all of those things are encouraging- we are trying to do these things to improve the outcomes for high-risk patients.